| Drug Name |
Lasofoxifene |
| Drug ID |
BADD_D01250 |
| Description |
Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008. It gained approval by European Commission in March 2009. Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA. |
| Indications and Usage |
Investigated for use/treatment in postmenopausal osteoporosis to reduce the risk of both vertebral and novertebral fractures, as well as address other postmenopausal conditions, including reduction in risk of breast cancer and treatment of vulvar and vaginal atrophy (VVA) |
| Marketing Status |
Not Available |
| ATC Code |
Not Available |
| DrugBank ID |
DB06202
|
| KEGG ID |
Not Available
|
| MeSH ID |
C111332
|
| PubChem ID |
216416
|
| TTD Drug ID |
D09NMD
|
| NDC Product Code |
Not Available |
| Synonyms |
Lasofoxifene | (-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol | CP 336156 | CP-336,156 | lasofoxifene hydrochloride | cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt | LAS estrogen receptor modulator |
